References
- 1 Ries L AG, E M, Kosary C L, Hankey B F, Miller B A, Clegg L, Edwards B K. SEER Cancer
Statistics Review. 2002
- 2
Landis S H. et al .
Cancer statistics, 1999.
CA Cancer J Clin.
1999;
49 (1)
8-31
- 3
Wallace M B. et al .
Endoscopic ultrasound-guided fine needle aspiration for staging patients with carcinoma
of the lung.
Ann Thorac Surg.
2001;
72 (6)
1861-1867
- 4
Gupta N C. et al .
Mediastinal lymph node sampling following positron emission tomography with fluorodeoxyglucose
imaging in lung cancer staging.
Chest.
2001;
120 (2)
521-527
- 5
Dwamena B A. et al .
Metastases from non-small cell lung cancer: mediastinal staging in the 1990s-meta-analytic
comparison of PET and CT.
Radiology.
1999;
213 (2)
530-536
- 6
Mountain C F, Dresler C M.
Regional lymph node classification for lung cancer staging.
Chest.
1997;
111 (6)
1718-1723
- 7
Dobashi K. et al .
Micrometastatic P53-positive cells in the lymph nodes of non-small-cell lung cancer:
prognostic significance.
J Thorac Cardiovasc Surg.
1997;
114 (3)
339-346
- 8
Dowlatshahi K. et al .
Lymph node micrometastases from breast carcinoma: reviewing the dilemma.
Cancer.
1997;
80 (7)
1188-1197
- 9
Izbicki J R. et al .
Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes
of patients with completely resected esophageal cancer.
N Engl J Med.
1997;
337 (17)
1188-1194
- 10
Miller J D, Gorenstein L A, Patterson G A.
Staging: the key to rational management of lung cancer.
Ann Thorac Surg.
1992;
53 (1)
170-178
- 11
Gress F G. et al .
Endoscopic ultrasonography, fine-needle aspiration biopsy guided by endoscopic ultrasonography,
and computed tomography in the preoperative staging of non-small-cell lung cancer:
a comparison study.
Ann Intern Med.
1997;
127 (8 Pt 1)
604-612
- 12
Wiersema M J. et al .
Preoperative staging of non-small cell lung cancer: transesophageal US-guided fine-needle
aspiration biopsy of mediastinal lymph nodes.
Radiology.
1994;
190 (1)
239-342
- 13
Fritscher-Ravens A. et al .
Mediastinal lymph node involvement in potentially resectable lung cancer: comparison
of CT, positron emission tomography, and endoscopic ultrasonography with and without
fine-needle aspiration.
Chest.
2003;
123 (2)
442-451
- 14
Harewood G C. et al .
Cost-minimization analysis of alternative diagnostic approaches in a modeled patient
with non-small cell lung cancer and subcarinal lymphadenopathy.
Mayo Clin Proc.
2002;
77 (2)
155-164
- 15
Gress F G. et al .
Endoscopic ultrasonography, fine-needle aspiration biopsy guided by endoscopic ultrasonography,
and computed tomography in the preoperative staging of non-small-cell lung cancer:
a comparison study [see comments].
Ann Intern Med.
1997;
127 (8 Pt 2)
604-612
- 16
Silvestri G A. et al .
Endoscopic ultrasound with fine-needle aspiration in the diagnosis and staging of
lung cancer.
Ann Thorac Surg.
1996;
61 (5)
1441-5; discussion 1445 - 1446
- 17
Wiersema M J. et al .
Preoperative staging of non-small cell lung cancer: transesophageal US-guided fine-needle
aspiration biopsy of mediastinal lymph nodes.
Radiology.
1994;
190 (1)
239-242
- 18
Salerno C T. et al .
Detection of occult micrometastases in non-small cell lung carcinoma by reverse transcriptase-polymerase
chain reaction.
Chest.
1998;
113 (6)
1526-1532
- 19
Maruyama R. et al .
Relationship between early recurrence and micrometastases in the lymph nodes of patients
with stage I non-small-cell lung cancer.
J Thorac Cardiovasc Surg.
1997;
114 (4)
535-543
- 20
Chen Z L. et al .
Frequency and distribution of occult micrometastases in lymph nodes of patients with
non-small-cell lung carcinoma.
J Natl Cancer Inst.
1993;
85 (6)
493-498
- 21
Wallace M B. et al .
Detection of telomerase expression in mediastinal lymph nodes of patients with lung
cancer.
Am J Respir Crit Care Med.
2003;
167 (12)
1670-1675
- 22
Wallace M B. et al .
Accurate molecular detection of non-small cell lung cancer metastases in mediastinal
lymph nodes sampled by endoscopic ultrasound-guided needle aspiration.
Chest.
2005;
127 (2)
430-437
- 23
Mori M. et al .
Detection of cancer micrometastases in lymph nodes by reverse transcriptase-polymerase
chain reaction.
Cancer Res.
1995;
55 (15)
3417-3420
- 24
Noguchi S. et al .
Detection of breast cancer micrometastases in axillary lymph nodes by means of reverse
transcriptase-polymerase chain reaction. Comparison between MUC1 mRNA and keratin
19 mRNA amplification.
Am J Pathol.
1996;
148 (2)
649-656
- 25
Lockett M A. et al .
Efficacy of reverse transcriptase-polymerase chain reaction screening for micrometastic
disease in axillary lymph nodes of breast cancer patients.
Am Surg.
1998;
64 (6)
539-43; discussion 543 - 4
- 26
Mitas M. et al .
Quantitative real-time RT-PCR detection of breast cancer micrometastasis using a multigene
marker panel.
Int J Cancer.
2001;
93 (2)
162-171
- 27
Hashimoto T. et al .
Prognostic value of genetically diagnosed lymph node micrometastasis in non-small
cell lung carcinoma cases.
Cancer Res.
2000;
60 (22)
6472-6478
- 28
Pallisgaard N. et al .
Rapid and sensitive minimal residual disease detection in acute leukemia by quantitative
real-time RT-PCR exemplified by t(12;21) TEL-AML1 fusion transcript.
Genes Chromosomes Cancer.
1999;
26 (4)
355-365
- 29
Mensink E. et al .
Quantitation of minimal residual disease in Philadelphia chromosome positive chronic
myeloid leukaemia patients using real-time quantitative RT-PCR.
Br J Haematol.
1998;
102 (3)
768-774
- 30
Emig M. et al .
Accurate and rapid analysis of residual disease in patients with CML using specific
fluorescent hybridization probes for real time quantitative RT-PCR.
Leukemia.
1999;
13 (11)
1825-1832
- 31
Cassinat B. et al .
Quantitation of minimal residual disease in acute promyelocytic leukemia patients
with t(15;17) translocation using real-time RT-PCR.
Leukemia.
2000;
14 (2)
324-328
- 32
Bostick P J. et al .
Limitations of specific reverse-transcriptase polymerase chain reaction markers in
the detection of metastases in the lymph nodes and blood of breast cancer patients.
J Clin Oncol.
1998;
16 (8)
2632-2640
- 33
Iwao K. et al .
Isolation of a novel human lung-specific gene, LUNX, a potential molecular marker
for detection of micrometastasis in non-small-cell lung cancer.
Int J Cancer.
2001;
91 (4)
433-437
- 34
Perez M S, Walker L E.
Isolation and characterization of a cDNA encoding the KS1/4 epithelial carcinoma marker.
J Immunol.
1989;
142 (10)
3662-3667
- 35
Latza U. et al .
Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelial.
J Clin Pathol.
1990;
43 (3)
213-219
- 36
Schwartzberg L S.
Clinical experience with edrecolomab: a monoclonal antibody therapy for colorectal
carcinoma.
Crit Rev Oncol Hematol.
2001;
40 (1)
17-24
- 37
Kim N W. et al .
Specific association of human telomerase activity with immortal cells and cancer.
Science.
1994;
266 (5193)
2011-2015
- 38
Kolquist K A. et al .
Expression of TERT in early premalignant lesions and a subset of cells in normal tissues.
Nat Genet.
1998;
19 (2)
182-186
- 39
Saretzki G. et al .
hTERT gene dosage correlates with telomerase activity in human lung cancer cell lines.
Cancer Lett.
2002;
176 (1)
81-91
- 40
Marchetti A. et al .
Prediction of survival in stage I lung carcinoma patients by telomerase function evaluation.
Lab Invest.
2002;
82 (6)
729-736
- 41
Toomey D. et al .
Immune function, telomerase, and angiogenesis in patients with primary, operable nonsmall
cell lung carcinoma: tumor size and lymph node status remain the most important prognostic
features.
Cancer.
2001;
92 (10)
2648-2657
- 42
Hara H. et al .
Clinicopathologic significance of telomerase activity and hTERT mRNA expression in
non-small cell lung cancer.
Lung Cancer.
2001;
34 (2)
219-226
- 43
Komiya T. et al .
Prognostic significance of hTERT expression in non-small cell lung cancer.
Int J Oncol.
2000;
16 (6)
1173-1177
- 44
Taga S. et al .
Prognostic impact of telomerase activity in non-small cell lung cancers.
Ann Surg.
1999;
230 (5)
715-720
- 45
Kim J K. et al .
Activation of telomerase by silica in rat lung.
Toxicol Lett.
2000;
111 (3)
263-270
- 46
Nozaki Y. et al .
Induction of telomerase activity in fibroblasts from bleomycin-injured lungs.
Am J Respir Cell Mol Biol.
2000;
23 (4)
460-465
- 47
Kumaki F. et al .
Telomerase activity and expression of human telomerase RNA component and human telomerase
reverse transcriptase in lung carcinomas.
Hum Pathol.
2001;
32 (2)
188-195
- 48
Xinarianos G. et al .
Evaluation of telomerase activity in bronchial lavage as a potential diagnostic marker
for malignant lung disease.
Lung Cancer.
2000;
28 (1)
37-42
- 49
Sumida T. et al .
Clinical usefulness of telomerase assay for the detection of lymph node metastasis
in patients with oral malignancy.
Arch Pathol Lab Med.
2000;
124 (3)
398-400
- 50
Nicholson R I, Gee J M, Harper M E.
EGFR and cancer prognosis.
Eur J Cancer.
2001;
37 Suppl 4
S9-15
- 51
Brabender J. et al .
Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung
cancer Is correlated with survival.
Clin Cancer Res.
2001;
7 (7)
1850-1855
- 52
Selvaggi G. et al .
Epidermal growth factor receptor overexpression correlates with a poor prognosis in
completely resected non-small-cell lung cancer.
Ann Oncol.
2004;
15 (1)
28-32
- 53
Swinson D E, Cox G, O’Byrne K J.
Coexpression of epidermal growth factor receptor with related factors is associated
with a poor prognosis in non-small-cell lung cancer.
Br J Cancer.
2004;
91 (7)
1301-1307
- 54
Sridhar S S, Seymour L, Shepherd F A.
Inhibitors of epidermal-growth-factor receptors: a review of clinical research with
a focus on non-small-cell lung cancer.
Lancet Oncol.
2003;
4 (7)
397-406
- 55
Kris M G. et al .
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine
kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
Jama.
2003;
290 (16)
2149-2158
- 56
Perez-Soler R. et al .
Determinants of tumor response and survival with erlotinib in patients with non-small-cell
lung cancer.
J Clin Oncol.
2004;
22 (16)
3238-3247
- 57
Lynch T J. et al .
Activating mutations in the epidermal growth factor receptor underlying responsiveness
of non-small-cell lung cancer to gefitinib.
N Engl J Med.
2004;
350 (21)
2129-2139
- 58
Paez J G. et al .
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
Science.
2004;
304 (5676)
1497-1500
- 59
Cappuzzo F. et al .
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell
lung cancer.
J Natl Cancer Inst.
2005;
97 (9)
643-655
- 60
Marchetti A. et al .
EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases
and development of a rapid and sensitive method for diagnostic screening with potential
implications on pharmacologic treatment.
J Clin Oncol.
2005;
23 (4)
857-865
- 61
Shigematsu H. et al .
Clinical and biological features associated with epidermal growth factor receptor
gene mutations in lung cancers.
J Natl Cancer Inst.
2005;
97 (5)
339-346
- 62
Yang S H. et al .
Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in
non-small cell lung cancer.
Clin Cancer Res.
2005;
11 (6)
2106-2110
- 63
Kim K S. et al .
Predictors of the response to gefitinib in refractory non-small cell lung cancer.
Clin Cancer Res.
2005;
11 (6)
2244-2251
- 64
Tsao M S. et al .
Erlotinib in lung cancer - molecular and clinical predictors of outcome.
N Engl J Med.
2005;
353 (2)
133-144
Michael B. Wallace, M.D.
Associate Professor of Medicine
Division of Gastroenterology and Hepatology
Mayo Clinic Jacksonville
4500 San Pablo Rd
Jacksonville, FL 32224
eMail: wallace.michael@mayo.edu
